8I5B
 
 | | Structure of human Nav1.7 in complex with bupivacaine | | 分子名称: | 1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE, 1-O-OCTADECYL-SN-GLYCERO-3-PHOSPHOCHOLINE, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | 著者 | Wu, Q.R, Yan, N. | | 登録日 | 2023-01-24 | | 公開日 | 2023-06-14 | | 最終更新日 | 2023-11-08 | | 実験手法 | ELECTRON MICROSCOPY (2.7 Å) | | 主引用文献 | Structural mapping of Na v 1.7 antagonists.
Nat Commun, 14, 2023
|
|
8I5Y
 | | Structure of human Nav1.7 in complex with vixotrigine | | 分子名称: | (2S,3R,4E)-2-(acetylamino)-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate, (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en, 1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE, ... | | 著者 | Wu, Q.R, Yan, N. | | 登録日 | 2023-01-26 | | 公開日 | 2023-06-14 | | 最終更新日 | 2023-11-08 | | 実験手法 | ELECTRON MICROSCOPY (2.6 Å) | | 主引用文献 | Structural mapping of Na v 1.7 antagonists.
Nat Commun, 14, 2023
|
|
8I5G
 | | Structure of human Nav1.7 in complex with PF-05089771 | | 分子名称: | (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en, 1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE, 1-O-OCTADECYL-SN-GLYCERO-3-PHOSPHOCHOLINE, ... | | 著者 | Wu, Q.R, Yan, N. | | 登録日 | 2023-01-25 | | 公開日 | 2023-06-14 | | 最終更新日 | 2023-11-08 | | 実験手法 | ELECTRON MICROSCOPY (2.7 Å) | | 主引用文献 | Structural mapping of Na v 1.7 antagonists.
Nat Commun, 14, 2023
|
|
8J4F
 | | Structure of human Nav1.7 in complex with Hardwickii acid | | 分子名称: | (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en, (4~{a}~{R},5~{S},6~{R},8~{a}~{R})-5-[2-(furan-3-yl)ethyl]-5,6,8~{a}-trimethyl-3,4,4~{a},6,7,8-hexahydronaphthalene-1-carboxylic acid, 1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE, ... | | 著者 | Wu, Q.R, Yan, N. | | 登録日 | 2023-04-19 | | 公開日 | 2023-06-14 | | 実験手法 | ELECTRON MICROSCOPY (3 Å) | | 主引用文献 | Structural mapping of Na v 1.7 antagonists.
Nat Commun, 14, 2023
|
|
7E3L
 | | Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 58G6 heavy chain, 58G6 light chain, ... | | 著者 | Guo, H, Li, T, Liu, F, Gao, Y, Ji, X, Yang, H. | | 登録日 | 2021-02-09 | | 公開日 | 2021-09-15 | | 最終更新日 | 2022-03-02 | | 実験手法 | ELECTRON MICROSCOPY (3.6 Å) | | 主引用文献 | Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants.
Nat Commun, 12, 2021
|
|
7E3K
 | | Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants | | 分子名称: | 13G9 heavy chain, 13G9 light chain, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | 著者 | Guo, H, Li, T, Liu, F, Gao, Y, Ji, X, Yang, H. | | 登録日 | 2021-02-09 | | 公開日 | 2021-09-15 | | 最終更新日 | 2022-03-02 | | 実験手法 | ELECTRON MICROSCOPY (3.9 Å) | | 主引用文献 | Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants.
Nat Commun, 12, 2021
|
|
4MCB
 | | H.influenzae TrmD in complex with N-(4-{[(1H-IMIDAZOL-2-YLMETHYL)AMINO]METHYL}BENZYL)-4-OXO-3,4-DIHYDROTHIENO[2,3-D]PYRIMIDINE-5-CARBOXAMIDE | | 分子名称: | ACETATE ION, GLYCEROL, N-(4-{[(1H-imidazol-2-ylmethyl)amino]methyl}benzyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide, ... | | 著者 | Olivier, N.B, Hill, P. | | 登録日 | 2013-08-21 | | 公開日 | 2013-09-04 | | 最終更新日 | 2024-02-28 | | 実験手法 | X-RAY DIFFRACTION (1.94 Å) | | 主引用文献 | Selective Inhibitors of Bacterial t-RNA-(N(1)G37) Methyltransferase (TrmD) That Demonstrate Novel Ordering of the Lid Domain.
J.Med.Chem., 56, 2013
|
|
5IQ7
 | | Crystal structure of 10E8-S74W Fab in complex with an HIV-1 gp41 peptide. | | 分子名称: | 10E8-S74W Heavy Chain, 10E8-S74W Light Chain, gp41 MPER peptide | | 著者 | Ofek, G, Kwon, Y.D, Caruso, W, Kwong, P.D. | | 登録日 | 2016-03-10 | | 公開日 | 2016-04-20 | | 最終更新日 | 2023-09-27 | | 実験手法 | X-RAY DIFFRACTION (3.2869 Å) | | 主引用文献 | Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design.
J.Virol., 90, 2016
|
|
4MCD
 | | hinTrmD in complex with 5-PHENYLTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE | | 分子名称: | 5-phenylthieno[2,3-d]pyrimidin-4(3H)-one, tRNA (guanine-N(1)-)-methyltransferase | | 著者 | Lahiri, S. | | 登録日 | 2013-08-21 | | 公開日 | 2013-09-25 | | 最終更新日 | 2024-02-28 | | 実験手法 | X-RAY DIFFRACTION (1.55 Å) | | 主引用文献 | Selective Inhibitors of Bacterial t-RNA-(N(1)G37) Methyltransferase (TrmD) That Demonstrate Novel Ordering of the Lid Domain.
J.Med.Chem., 56, 2013
|
|
4MCC
 | | HinTrmD in complex with N-[4-(AMINOMETHYL)BENZYL]-4-OXO-3,4-DIHYDROTHIENO[2,3-D]PYRIMIDINE-5-CARBOXAMIDE | | 分子名称: | N-[4-(aminomethyl)benzyl]-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide, tRNA (guanine-N(1)-)-methyltransferase | | 著者 | Olivier, N.B, Hill, P. | | 登録日 | 2013-08-21 | | 公開日 | 2013-09-04 | | 最終更新日 | 2024-02-28 | | 実験手法 | X-RAY DIFFRACTION (1.95 Å) | | 主引用文献 | Selective Inhibitors of Bacterial t-RNA-(N(1)G37) Methyltransferase (TrmD) That Demonstrate Novel Ordering of the Lid Domain.
J.Med.Chem., 56, 2013
|
|
7LZ4
 | | Crystal structure of A211D mutant of Protein Kinase A RIa subunit, a Carney Complex mutation | | 分子名称: | ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE, cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed | | 著者 | Del Rio, J, Wu, J, Taylor, S.S. | | 登録日 | 2021-03-08 | | 公開日 | 2021-05-26 | | 最終更新日 | 2023-10-18 | | 実験手法 | X-RAY DIFFRACTION (4.155 Å) | | 主引用文献 | Noncanonical protein kinase A activation by oligomerization of regulatory subunits as revealed by inherited Carney complex mutations.
Proc.Natl.Acad.Sci.USA, 118, 2021
|
|
7V1N
 | | Structure of the Clade 2 C. difficile TcdB in complex with its receptor TFPI | | 分子名称: | Isoform Beta of Tissue factor pathway inhibitor, Toxin B | | 著者 | Luo, J, Yang, Q, Zhang, X, Zhang, Y, Wan, L, Li, Y, Tao, L. | | 登録日 | 2021-08-05 | | 公開日 | 2022-02-23 | | 最終更新日 | 2022-03-30 | | 実験手法 | ELECTRON MICROSCOPY (3.2 Å) | | 主引用文献 | TFPI is a colonic crypt receptor for TcdB from hypervirulent clade 2 C. difficile.
Cell, 185, 2022
|
|
5IQ9
 | | Crystal structure of 10E8v4 Fab in complex with an HIV-1 gp41 peptide. | | 分子名称: | 10E8v4 Heavy Chain, 10E8v4 Light Chain, gp41 MPER peptide | | 著者 | Ofek, G, Kwon, Y.D, Caruso, W, Kwong, P.D. | | 登録日 | 2016-03-10 | | 公開日 | 2016-04-20 | | 最終更新日 | 2023-09-27 | | 実験手法 | X-RAY DIFFRACTION (2.4 Å) | | 主引用文献 | Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design.
J.Virol., 90, 2016
|
|
8V2E
 | |
7SP0
 | |
7CH1
 | | The overall structure of SLC26A9 | | 分子名称: | CHLORIDE ION, SODIUM ION, Solute carrier family 26 member 9 | | 著者 | Chi, X.M, Chen, Y, Li, X.R, Zhang, Y.Y, Zhou, Q. | | 登録日 | 2020-07-03 | | 公開日 | 2020-08-26 | | 最終更新日 | 2024-03-27 | | 実験手法 | ELECTRON MICROSCOPY (2.6 Å) | | 主引用文献 | Structural insights into the gating mechanism of human SLC26A9 mediated by its C-terminal sequence.
Cell Discov, 6, 2020
|
|
7UR4
 | |
7E8I
 | | Structural insight into BRCA1-BARD1 complex recruitment to damaged chromatin | | 分子名称: | BRCA1-associated RING domain protein 1, DNA (145-MER), Histone H2A, ... | | 著者 | Dai, Y, Dai, L, Zhou, Z. | | 登録日 | 2021-03-01 | | 公開日 | 2021-06-30 | | 最終更新日 | 2024-03-27 | | 実験手法 | ELECTRON MICROSCOPY (3.1 Å) | | 主引用文献 | Structural insight into BRCA1-BARD1 complex recruitment to damaged chromatin.
Mol.Cell, 81, 2021
|
|
5V0Y
 | |
7Y99
 | | Crystal Structure Analysis of cp2 bound BCLxl | | 分子名称: | Bcl-2-like protein 1, CP2 peptide, N-(2-acetamidoethyl)-4-(4,5-dihydro-1,3-thiazol-2-yl)benzamide | | 著者 | Li, F.W, Liu, C, Wu, C.L, Wu, D.L. | | 登録日 | 2022-06-24 | | 公開日 | 2023-09-27 | | 最終更新日 | 2024-02-28 | | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | | 主引用文献 | Cyclic peptides discriminate BCL-2 and its clinical mutants from BCL-X L by engaging a single-residue discrepancy.
Nat Commun, 15, 2024
|
|
7YAA
 | | Crystal structure analysis of cp3 bound BCLxl | | 分子名称: | Bcl-2-like protein 1, GLYCEROL, N-(2-acetamidoethyl)-4-(4-methanoyl-1,3-thiazol-2-yl)benzamide, ... | | 著者 | Li, F.W, Liu, C, Wu, C.L, Wu, D.L. | | 登録日 | 2022-06-27 | | 公開日 | 2023-11-15 | | 最終更新日 | 2024-02-28 | | 実験手法 | X-RAY DIFFRACTION (1.4 Å) | | 主引用文献 | Cyclic peptides discriminate BCL-2 and its clinical mutants from BCL-X L by engaging a single-residue discrepancy.
Nat Commun, 15, 2024
|
|
7Y90
 | | Crystal Structure Analysis of cp1 bound BCL2 | | 分子名称: | (2R)-3-[2-(aminomethyl)-3-azanyl-1-[4-[2-(2-chloranylethanoylamino)ethylcarbamoyl]phenyl]prop-1-enyl]sulfanyl-2-(carboxyamino)propanoic acid, Apoptosis regulator Bcl-2, cp1 peptide | | 著者 | Li, F.W. | | 登録日 | 2022-06-24 | | 公開日 | 2023-11-15 | | 最終更新日 | 2024-02-28 | | 実験手法 | X-RAY DIFFRACTION (2.09 Å) | | 主引用文献 | Cyclic peptides discriminate BCL-2 and its clinical mutants from BCL-X L by engaging a single-residue discrepancy.
Nat Commun, 15, 2024
|
|
7Y8D
 | | Crystal structure of cp1 bound BCLxl | | 分子名称: | (2R)-3-[2-(aminomethyl)-3-azanyl-1-[4-[2-(2-chloranylethanoylamino)ethylcarbamoyl]phenyl]prop-1-enyl]sulfanyl-2-(carboxyamino)propanoic acid, Bcl-2-like protein 1, cp1 peptide | | 著者 | Li, F.W, Liu, C, Wu, C.L, Wu, D.L. | | 登録日 | 2022-06-23 | | 公開日 | 2023-11-15 | | 最終更新日 | 2024-02-28 | | 実験手法 | X-RAY DIFFRACTION (2 Å) | | 主引用文献 | Cyclic peptides discriminate BCL-2 and its clinical mutants from BCL-X L by engaging a single-residue discrepancy.
Nat Commun, 15, 2024
|
|
7YA5
 | | Crystal structure analysis of cp1 bound BCL2/G101V | | 分子名称: | (2R)-3-[2-(aminomethyl)-3-azanyl-1-[4-[2-(2-chloranylethanoylamino)ethylcarbamoyl]phenyl]prop-1-enyl]sulfanyl-2-(carboxyamino)propanoic acid, Apoptosis regulator Bcl-2, cp1 peptide | | 著者 | Li, F.W, Liu, C, Wu, C.L, Wu, D.L. | | 登録日 | 2022-06-27 | | 公開日 | 2023-11-15 | | 最終更新日 | 2024-02-28 | | 実験手法 | X-RAY DIFFRACTION (1.85 Å) | | 主引用文献 | Cyclic peptides discriminate BCL-2 and its clinical mutants from BCL-X L by engaging a single-residue discrepancy.
Nat Commun, 15, 2024
|
|
7YB7
 | | anti-apoptotic protein BCL-2-M12 | | 分子名称: | Apoptosis regulator Bcl-2,Bcl-2-like protein 1, N-(2-acetamidoethyl)-4-(4,5-dihydro-1,3-thiazol-2-yl)benzamide, cp2 peptide | | 著者 | Li, F.W, Liu, C, Wu, D.L. | | 登録日 | 2022-06-29 | | 公開日 | 2023-11-15 | | 最終更新日 | 2024-02-28 | | 実験手法 | X-RAY DIFFRACTION (2.2 Å) | | 主引用文献 | Cyclic peptides discriminate BCL-2 and its clinical mutants from BCL-X L by engaging a single-residue discrepancy.
Nat Commun, 15, 2024
|
|
